The estimated Net Worth of Hugh M. O'neill is at least 4.43 百万$ dollars as of 14 November 2017. Mr. neill owns over 9,000 units of Mallinckrodt Plc stock worth over 13,701$ and over the last 11 years he sold MNK stock worth over 0$. In addition, he makes 4,412,780$ as Executive Vice President、 Chief Commercial Officer at Mallinckrodt Plc.
Sign up
Mr. Neill MNK stock SEC Form 4 insiders trading
Hugh has made over 5 trades of the Mallinckrodt Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of MNK stock worth 196,200$ on 14 November 2017.
The largest trade he's ever made was buying 9,000 units of Mallinckrodt Plc stock on 14 November 2017 worth over 196,200$. On average, Hugh trades about 680 units every 41 days since 2014. As of 14 November 2017 he still owns at least 40,297 units of Mallinckrodt Plc stock.
You can see the complete history of Mr. neill stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Hugh O'Neill biography
Hugh O'Neill is Executive Vice President, Chief Commercial Officer of the Company. He has executive responsibility for the Company's Specialty Brands products, directly managing all commercialization efforts and broad market access activities, as well as new product launch execution for assets in Mallinckrodt's near-term development portfolio. From April 2015 to May 2018, Mr. O'Neill served as our Executive Vice President and President, Autoimmune and Rare Diseases, and from September 2013 to April 2015, he served as Senior Vice President and President, U.S. Specialty Pharmaceuticals. Prior to joining Mallinckrodt in September 2013, Mr. O'Neill worked at Sanofi-Aventis for ten years where he held various commercial leadership positions including Vice President of Commercial Excellence from June 2012 to July 2013; General Manager, President of Sanofi-Aventis Canada from June 2009 to May 2012; and Vice President Market Access and Business Development from 2006 to 2009. Mr. O'Neill joined Sanofi in 2003 as its Vice President, United States Managed Markets. Mr. O'Neill previously served in a variety of positions of increasing responsibility for Sandoz Pharmaceuticals, Forest Laboratories, Novartis Pharmaceuticals and Pfizer Inc
What is the salary of Hugh Neill?
As the Executive Vice President、 Chief Commercial Officer of Mallinckrodt Plc, the total compensation of Hugh Neill at Mallinckrodt Plc is 4,412,780$. There are 2 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of 14,610,800$.
How old is Hugh Neill?
Hugh Neill is 56, he's been the Executive Vice President、 Chief Commercial Officer of Mallinckrodt Plc since 2018. There are 10 older and 2 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
What's Hugh Neill's mailing address?
Hugh's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Insiders trading at Mallinckrodt Plc
Over the last 11 years, insiders at Mallinckrodt Plc have traded over 29,853,069$ worth of Mallinckrodt Plc stock and bought 2,559,592 units worth 174,429,961$ . The most active insiders traders include & Co. Inc. Paulson、James E Deerfield Mgmt L.P....、Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of 10,061$. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth 9,495$.
What does Mallinckrodt Plc do?
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
What does Mallinckrodt Plc's logo look like?
Complete history of Mr. neill stock trades at Mallinckrodt Plc
Mallinckrodt Plc executives and stock owners
Mallinckrodt Plc executives and other stock owners filed with the SEC include:
-
Mark Trudeau,
President, Chief Executive Officer, Director -
Steven Romano,
Executive Vice President, Chief Scientific Officer -
Hugh O'Neill,
Executive Vice President, Chief Commercial Officer -
Mark Casey,
Executive Vice President and Chief Legal Officer -
Bryan Reasons,
Chief Financial Officer, Executive Vice President -
Ian Watkins,
Chief Human Resource Officer, Executive Vice President -
Angus Russell,
Independent Non-Executive Chairman of the Board -
JoAnn Reed,
Independent Director -
J. Martin Carroll,
Independent Director -
David Norton,
Independent Director -
Kneeland Youngblood,
Independent Director -
Anne Whitaker,
Independent Director -
Paul Carter,
Independent Director -
Carlos Paya,
Independent Director -
Daniel Speciale,
Vice President - Investor Relations and IRO -
David R Carlucci,
Director -
Virgil D Thompson,
Director -
Diane H. Gulyas,
Director -
Matthew K Harbaugh,
SVP&Chief Financial Officer -
Michael Bryant Hicks,
Sr. VP & General Counsel -
Ronald K. Lloyd,
Sr. VP & Pres, Hospital -
Raymond J. Furey,
SVP & Chief Compliance Officer -
Gary M. Phillips,
Sr. VP & Chief Strategy Ofcr. -
Meredith B Fischer,
SVP, Communic. & Public Affair -
Melvin D Booth,
Director -
Joseph A Zaccagnino,
Director -
Coleman N Iii Lannum,
VP, Investor Relations -
Dagmar Rosa Bjorkeson,
Chief Strat & Corp Dev Officer -
Sigurdur O Olafsson,
President and CEO -
Kassie Harrold,
Chief Compliance Officer -
Jason Daniel Goodson,
EVP & Head of Corp Development -
Henriette Nielsen,
EVP & Chief Transformation OFC -
Lisa French,
EVP & Chief Commercial Officer -
Mark Anthony Tyndall,
EVP & Chief Legal Offi & Secre -
Stephen Andrew Welch,
EVP & Head of Spec Generics -
Frank Scholz,
SVP, Global Operations -
George A. Kegler,
EVP & CFO, Interim -
Karen Patruno Sheehy,
Sr. VP & Chief Compliance Off. -
James E Deerfield Mgmt L.P....,
-
Don M Bailey,
Director -
Sandra L Hatten,
Sr. Vice President Quality -
Terrance L Carlson,
Interim General Counsel -
& Co. Inc. Paulson,
10% owner -
Holding Ltd Enceladus,
-
Thomas E Berry,
See Remarks -
Peter G Edwards,
See Remarks -
Stefano R Carchedi,
See Remarks -
Stephen Merrick,
See Remarks -
Nancy Lurker,
Director -
Mario D. Saltarelli,
Sr. VP & Chief Science Ofcr. -
Kathy A Schaefer,
Sr. VP Fin & Corp. Controller -
Peter C Richardson,
EVP & Chief Scientific Officer -
Daniel Arthur Celentano,
Director -
Woodrow A Jr Myers,
Director -
Paul Bisaro,
Director -
James R Sulat,
Director -
Susan Michele Silbermann,
Director -
Karen Ling,
Director -
Neal P Goldman,
Director -
Riad Hussein El Dada,
Director